Press release
Deadline on January 14th in Lawsuit for Investors in Lipocine Inc. (NASDAQ: LPCN) coming up
A Deadline is coming up on January 14, 2020 in the lawsuit for certain investors in Lipocine Inc. (NASDAQ: LPCN).
Investors who purchased shares of Lipocine Inc. (NASDAQ: LPCN) have certain options and there are strict and short deadlines running. Deadline: January 14, 2020. NASDAQ: LPCN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the District of Utah the plaintiff alleges on behalf of purchasers of Lipocine Inc. (NASDAQ: LPCN) common shares between March 27, 2019, and November 8, 2019, that the defendants violated Federal Securities Laws.
More specifically, the plaintiff claims that between March 27, 2019, and November 8, 2019, the defendants made false and/or misleading statements and/or failed to disclose that the results from Lipocine’s clinical studies of TLANDO were insufficient to demonstrate the drug’s efficacy, that accordingly, Lipocine’s third NDA for TLANDO was highly likely to be found deficient by the FDA, and that as a result, the Company’s public statements were materially false and misleading at all relevant times.
Those who purchased shares of Lipocine Inc. (NASDAQ: LPCN) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Deadline on January 14th in Lawsuit for Investors in Lipocine Inc. (NASDAQ: LPCN) coming up here
News-ID: 1896126 • Views: …
More Releases from Shareholders Foundation
Lawsuit DEADLINE Alert: Investors who lost money with Stride, Inc. (NYSE: LRN) s …
An investor, who purchased shares of Stride, Inc. (NYSE: LRN), filed a lawsuit over alleged violations of Federal Securities Laws by Stride, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Stride, Inc. (NYSE: LRN) have certain options and for certain investors are short and strict deadlines running. Deadline: January 12, 2026. NYSE: LRN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders…
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced.
Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:…
More Releases for Lipocine
Sarcopenia Market Insights Highlight Expanding Outlook Till 2034, DelveInsight E …
The Key Sarcopenia Companies in the market inlcude- TNF Pharmaceuticals, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirscience Therapeutics, Turn Biotechnologies, NMD PHARMA, ImmunoForge, Dong Wha PHARM, and others.
DelveInsight's "Sarcopenia Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Sarcopenia, historical and forecasted epidemiology as well as the Sarcopenia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and…
Sarcopenia Market Positioned for Accelerated Development Through 2034, DelveInsi …
The Key Sarcopenia Companies in the market include - TNF Pharmaceuticals, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirscience Therapeutics, Turn Biotechnologies, NMD PHARMA, ImmunoForge, Dong Wha PHARM, and others.
DelveInsight's "Sarcopenia Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Sarcopenia, historical and forecasted epidemiology as well as the Sarcopenia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom…
Postpartum Depression Clinical Trials, Companies, Therapeutic Assessment, Therap …
DelveInsight's, "Postpartum Depression - Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Postpartum Depression pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight's analysis reveals that the Postpartum Depression pipeline includes over…
Postpartum Depression Clinical Trials, Companies, Therapeutic Assessment, Therap …
DelveInsight's, "Postpartum Depression - Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Postpartum Depression pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
According to DelveInsight, the Postpartum Depression pipeline features over 10…
Cirrhosis Pipeline Insight | Companies- GWOXI Stem Cell Applied Technology, Lipo …
DelveInsight's, "Cirrhosis Pipeline Insight 2023" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Cirrhosis pipeline landscape. It covers the Cirrhosis pipeline drug profiles, including Cirrhosis clinical trials and nonclinical stage products. It also covers the Cirrhosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
To explore more information on the latest…
Investigation for Long-Term Investors in shares of Lipocine Inc. (NASDAQ: LPCN) …
An investigation was announced for current long-term investors in shares of Lipocine Inc. (NASDAQ: LPCN) concerning potential breaches of fiduciary duties by certain directors of Lipocine Inc. was announced.
Investors who are current long term investors in Lipocine Inc. (NASDAQ: LPCN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
